Drug firm’s legal action against government advisers is described as “intimidation”BMJ 2010; 341 doi: https://doi.org/10.1136/bmj.c6527 (Published 17 November 2010) Cite this as: BMJ 2010;341:c6527
- Ray Moynihan
- 1Byron Bay, Australia
The drug company AstraZeneca has launched legal action against an influential committee of independent advisers to the Australian government.
Documents lodged with a federal court show that the company has begun proceedings against 17 members of the Pharmaceutical Benefits Advisory Committee and the federal health minister.
Neither AstraZeneca nor the government will comment on the nature of the case against the powerful committee, which makes recommendations on which drugs attract subsidies—and the conditions attached to those subsidies—in Australia’s £4bn (€4.7bn; $6.4bn) publicly …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial